Anticancer Activity of Alectinib through Hydroxypropyl-β-Cyclodextrin Complexation: In Vitro Evaluation on A549 Lung Cancer Cells
Drug Research · 01.01.2026 · 76 (01) · 28-34
DOI: 10.1055/a-2764-8938 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Research, erschienen am 01.01.2026. Verfasst von Muathe Najim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacology, Al-Ahliyaa Amman University, Amman, Jordan. Hauptthemen laut MEDLINE: Carbazoles, Piperidines, Lung Neoplasms, 2-Hydroxypropyl-beta-cyclodextrin. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Alectinib is an effective inhibitor of anaplastic lymphoma kinase utilized in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer. Nonetheless, its limited solubility in water restricts its therapeutic effectiveness. This research seeks to improve the anticancer efficacy of alectinib through the formation of an inclusion complex with hydroxypro-pyl-β-cyclodextrin. The alectinib–hydroxypro-pyl-β-cyclodextrin complex was synthesized via the kneading method and characterized according to established studies. In vitro assays, such as cell viability (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay), colony formation, scratch wound healing, and tube formation assays, were conducted to assess the antiproliferative, antimigratory, and antiangiogenic activities of the complex in comparison to free alectinib. The alectinib–hydroxypro-pyl-β-cyclodextrin complex exhibited markedly increased cy-totoxicity, diminished colony formation, inhibited cell migration, and impaired tube formation compared to free alectinib. The findings indicate that hydroxypro-pyl-β-cyclodextrin complexation enhances the solubility and anticancer efficacy of alectinib, presenting a viable strategy for improving its therapeutic potential in the treatment of non-small-cell lung cancer. Alectinib, in conjunction with hydroxypropyl-β-cyclodextrin, was evaluated for its effects on A549 cells, which are representative of non-small-cell lung cancer. This study focused on its anticancer activity and its influence on cell migration. Angiogenesis refers to the physiological process through which new blood vessels form from pre-existing vessels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacology, Al-Ahliyaa Amman University, Amman, Jordan.
- Pharmaceutics and Pharmaceutical Technology, Al-Ahliyya Amman University, Amman, Jordan.
- Department of Pharmacy, Middle East University, Amman, Jordan.
- Department of Pharmacy, American University of Madaba, Amman, Jordan.
- Department of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden Heights, Malaysia.
- Department of Pharmaceutical Sciences, Faculty of Pharmacology, Al-Ahliyaa Amman University, Amman, Jordan.
ORCID-Profile: Israa Al-Ani
Zitieren
APA
Najim, M., Al-Ani, I., Al-Deeb, I., Majeed, B. J. M., Ata, T., & Daoud, E. (2026). Anticancer Activity of Alectinib through Hydroxypropyl-β-Cyclodextrin Complexation: In Vitro Evaluation on A549 Lung Cancer Cells. Drug Research, 76(01), 28-34. https://doi.org/10.1055/a-2764-8938
Vancouver
Najim M, Al-Ani I, Al-Deeb I, Majeed BJM, Ata T, Daoud E. Anticancer Activity of Alectinib through Hydroxypropyl-β-Cyclodextrin Complexation: In Vitro Evaluation on A549 Lung Cancer Cells. Drug Research. 2026;76(01):28-34. doi:10.1055/a-2764-8938
BibTeX
@article{Najim2026,
author = {Najim, Muathe and Al-Ani, Israa and Al-Deeb, Ibraheem and Majeed, Bashar J M and Ata, Tha'er and Daoud, Enass},
title = {Anticancer Activity of Alectinib through Hydroxypropyl-β-Cyclodextrin Complexation: In Vitro Evaluation on A549 Lung Cancer Cells},
journal = {Drug Research},
year = {2026},
volume = {76},
number = {01},
pages = {28--34},
doi = {10.1055/a-2764-8938}
}
EUVIMED